Search

Introduction: Quality and safety is a core competency, yet there are limited formalised quality improvement (QI) courses for physician trainees offered in Australia. Methods: An introductory QI workshop was conducted for trainees at the Internal Medicine Society of Australia and New Zealand (IMSANZ) Conference 2022. The workshop covered principles of improvement science, QI tools and plan-do-study-act (PDSA) cycles. The contents were delivered through a small-group experiential learning format. Pre- and post-workshop surveys were administered to evaluate the participants' perceptions and improvement in QI knowledge domains. Results: Thirty-five trainees attended the workshop. Of all respondents, none had received formal QI training previously. Statistically significant improvements in nearly all QI knowledge domains were noted in the post-workshop evaluation along with improvement in participants' motivation to further learn QI processes relevant to their vocation. Conclusion: An introductory workshop can significantly improve knowledge and motivation to further learn QI amongst physician trainees. [ABSTRACT FROM AUTHOR]

Objectives: To investigate differences in the incidence of enteropathy or intestinal malabsorption in patients taking angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitor (ACEI), calcium channel blocker (CCB), and beta blockers (BBs) at a single center in Korea., Methods: In this retrospective study, we utilized data from the Yangsan electronic medical records to identify 129,169 patients. These individuals were prescribed olmesartan, other ARBs, ACEI, CCB, and BBs between November 2008 and February 2021., Results: Of the 44,775 patients, 51 (0.11%) were observed to have enteropathy or intestinal malabsorption. Compared with the ACEI group, the adjusted odds ratios (ORs) for enteropathy and intestinal malabsorption were OR=1.313 (95% confidence interval [CI]: [0.188-6.798], p =0.893) for olmesartan, OR=0.915 (95% CI: [0.525-1.595], p =0.754) for the other ARBs, OR=0.928 (95% CI: [0.200-4.307]; p =0.924) for the CCB, and OR=0.663 (95% CI: [0.151-2.906]; p =0.586) for the BBs group. These findings were adjusted for factors such as age, gender, duration of antihypertensive medication, and comorbidities., Conclusion: In a retrospective cohort study of patients on antihypertensive medications, no significant difference was found in the incidence of enteropathy or intestinal malabsorption when ACEI was compared to olmesartan, other ARBs, CCB, and BBs., (Copyright: © Saudi Medical Journal.)